Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis

Table 1 Outcomes of randomized controlled trials included in the review

Ref.	Country	NCT number/Name	Treatment arm	N	mOS (mo)	pN0 rate	Resection rate	R0 rate	ITT R0 rate
Golcher et al[7]	Germany	NCT00335543	Upfront surgery	33	14.4	10/33 (30%)	23/33 (70%)	16/23 (70%)	16/33 (48%)
			GEM/CIS + RT	33	17.4	13/33 (39%)	19/33 (58%)	17/19 (89%)	17/33 (52%)
Versteijne et al[8]	Netherlands	PREOPANC	Upfront surgery	68	14.6	NM	54/68 (79%)	32/54 (59%)	32/68 (47%)
			GEM + RT	65	15.6	NM	44/65 (68%)	29/44 (66%)	29/65 (45%)
Casadei et al[9]	Italy	-	Upfront surgery	20	19.5	2/20 (10%)	15/20 (75%)	5/15 (33%)	5/20 (25%)
			GEM + RT	18	22.4	5/18 (28%)	11/18(61%)	7/11 (64%)	7/18 (39%)
Reni et al[10]	Italy	PACT-15	Upfront surgery (GEM)	26	20.4	6/22 (27%)	22/26 (84%)	6/22 (27%)	6/26 (23%)
			Upfront surgery (PEXG)	30	26.4	7/27 (26%)	27/30 (90%)	10/27 (37%)	10/30 (33%)
			PEXG	32	38.2	13/27 (48%)	27/32 (84%)	17/27 (63%)	17/32 (53%)
Satoi et al[11]	Japan	Prep-02/JSAP-05	Upfront surgery	180	26.3	NM	72%	NM	NM
			GEM + S-1	182	36.7	NM	77%	NM	NM

CIS: Cisplatin; GEM: Gemcitabine; RT: Radiotherapy; PEXG: Cisplatin, epirubicin, capecitabine, and gemcitabine; mOS: Median overall survival; pN0: Pathological N0; NM: Not mentioned; ITT: Intention to treat.